Hims & Hers Health HIMS
Hims & Hers Health Q2 FY25: revenue $544.8M, up 73%; diluted EPS $0.17
- Form
- 10-Q
- Filed
- Period
- Importance
- Notable
- Accession
- 0001773751-25-000250
- Document
- 10-Q
- Exhibit 10.3
- Material contract
Key figures from this report
These are the numbers Hims & Hers Health reported for Q2 FY25, the quarter ended Jun 30, 2025, as tagged in the filing’s XBRL data, each against the same quarter a year earlier. A plain-English reading of this report is not written yet.
- Revenue$544.8M+73% from $315.6M in Q2 FY2410-Q income statement, on EDGAR
- Net income$42.5M+220% from $13.3M in Q2 FY2410-Q income statement, on EDGAR
- Diluted EPS$0.17+183% from $0.06 in Q2 FY2410-Q income statement, on EDGAR
- Cash and cash equivalents$1.1B+770% from $129.3M in Q2 FY24Cash and equivalents only; the company page adds short-term investments.10-Q balance sheet, on EDGAR
- Cash from operations−$19.1M−136% from $53.6M in Q2 FY2410-Q cash flow statement, on EDGAR; the filing reports year-to-date cash flows; this quarter is the year-to-date total less the earlier quarters
Similar companies
Companies of similar size in SIC 8011 and related industry codes: the same peer list as the financial tables.
- Teladoc Health TDOC public float $1.5B, Jun 30, 2025
- LifeMD LFMD public float $512M, Jun 30, 2025
- Starling Oncology TOI public float $137M, Jun 30, 2025
- Airsculpt Technologies AIRS public float $80M, Jun 30, 2025
- SBC Medical Group Holdings SBC public float $48M, Jun 30, 2025
